
Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
Episode 391
Pharma partnering in China is getting earlier and broader, with Merck & Co., Novo Nordisk and Novartis striking multibillion-dollar deals for assets spanning new modalities and disease areas. On the latest BioCentury This Week podcast, BioCentury's analysts assess the trend and why co-development deals could draw scrutiny in Washington. The analysts also discuss the complexities of Beam's trade secret suit against YolTech, why the GLOBE Medicare pricing model matters more for the precedent it sets than for its savings, and the Nobel Prize for optogenetics as the first therapy based on the technology nears an FDA decision. View full story: https://www.biocentury.com/article/661028 #ChinaBiotech #DrugPricing #IntellectualProperty #DrugDevelopment #NobelPrize 0:00 Introduction 1:30 China Pharma Deal Trends 11:29 Beam vs. YolTech Lawsuit 20:01 Small GLOBE, Big Precedent 24:05 Nobel Prize & Optogenetics To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text
Publisher
BioCentury This Week
Published
October 6, 2026
Duration
30 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BioCentury
BioCentury This Week
@biocenturythisweek
#chinadeals #beamlawsuit #nobelwinners #lifesciences
